Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles from West Midlands
Based on 9 articles published since 2008
||||

These are the 9 published articles about Mesothelioma that originated from West Midlands during 2008-2019.
 
+ Citations + Abstracts
1 Guideline Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma. 2018

Woolhouse, Ian / Maskell, Nick A. ·Department of Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. · Academic Respiratory Unit, Southmead Hospital, University of Bristol, Bristol, UK. ·Thorax · Pubmed #29444989.

ABSTRACT: -- No abstract --

2 Guideline British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. 2018

Woolhouse, Ian / Bishop, Lesley / Darlison, Liz / De Fonseka, Duneesha / Edey, Anthony / Edwards, John / Faivre-Finn, Corinne / Fennell, Dean A / Holmes, Steve / Kerr, Keith M / Nakas, Apostolos / Peel, Tim / Rahman, Najib M / Slade, Mark / Steele, Jeremy / Tsim, Selina / Maskell, Nick A. ·Department of Respiratory Medicine, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK. · Respiratory Medicine, University Hospitals of Leicester, Leicester, UK. · Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK. · North Bristol NHS Trust, Bristol, UK. · Sheffield Teaching Hospitals, Sheffield, UK. · Division of Cancer Services, University of Manchester, Manchester, UK. · University of Leicester & University Hospitals of Leicester, Leicester, UK. · The Park Medical Practice, Shepton Mallet, Somerset, UK. · University of Aberdeen, Pathology, Aberdeen, UK. · Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK. · North Tyneside General Hospital, North Shields, UK. · Oxford NIHR Biomedical Research, University of Oxford, Oxford, UK. · Papworth Hospital, Thoracic Oncology, Cambridge, UK. · Cancer, St Bartholomew's Hospital, London, UK. · Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, UK. · Academic Respiratory Unit, Bristol Medical School, University of Bristol, Bristol, UK. ·Thorax · Pubmed #29444986.

ABSTRACT: -- No abstract --

3 Guideline Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. 2018

Husain, Aliya Noor / Colby, Thomas V / Ordóñez, Nelson G / Allen, Timothy Craig / Attanoos, Richard Luther / Beasley, Mary Beth / Butnor, Kelly Jo / Chirieac, Lucian R / Churg, Andrew M / Dacic, Sanja / Galateau-Sallé, Françoise / Gibbs, Allen / Gown, Allen M / Krausz, Thomas / Litzky, Leslie Anne / Marchevsky, Alberto / Nicholson, Andrew G / Roggli, Victor Louis / Sharma, Anupama K / Travis, William D / Walts, Ann E / Wick, Mark R. ·From the Department of Pathology, University of Chicago Medical Center, Chicago, Illinois (Drs Husain and Krausz) · the Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona (Dr Colby, emeritus) · the Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston (Dr Ordóñez) · the Department of Pathology, University of Texas Medical Branch, Galveston (Dr Allen) · the Department of Cellular Pathology, University Hospital of Wales and Cardiff University, Cardiff, South Glamorgan, Wales (Dr Attanoos) · the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley) · the Department of Pathology, University of Vermont College of Medicine, Burlington (Dr Butnor) · the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Chirieac) · the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg) · the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic) · Centre National Référent MESOPATH Departement de Biopathologie, Lyon Cedex, France (Dr Galateau-Sallé) · the Department of Pathology, University Hospital of Wales, Penarth, South Glamorgan, Wales (Dr Gibbs) · the Department of Pathology, PhenoPath Laboratories, Seattle, Washington (Dr Gown) · the Department of Pathology & Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, (Dr Litzky) · the Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California (Drs Marchevsky and Walts) · the Department of Histopathology, Royal Brompton & Harefield National Health Service Foundation Trust and the National Heart and Lung Institute, Imperial College, Chelsea, London, England (Dr Nicholson) · the Department of Pathology, Duke University Medical Center, Durham, North Carolina (Dr Roggli) · the Department of Pathology, University of Pittsburgh, and the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania (Dr Sharma) · the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Travis) · and the Department of Pathology, University of Virginia Medical Center, Charlottesville (Dr Wick). ·Arch Pathol Lab Med · Pubmed #28686500.

ABSTRACT: CONTEXT: - Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: - To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: - Pathologists involved in the International Mesothelioma Interest Group and others with an interest and expertise in the field contributed to this update. Reference material included up-to-date, peer-reviewed publications and textbooks. CONCLUSIONS: - There was discussion and consensus opinion regarding guidelines for (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) recognition of the key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid MM, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels employed is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Depending on the morphology, immunohistochemical panels should contain both positive and negative markers for mesothelial differentiation and for lesions considered in the differential diagnosis. Immunohistochemical markers should have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic and membranous markers). Selected molecular markers are now being used to distinguish benign from malignant mesothelial proliferations. These guidelines are meant to be a practical diagnostic reference for the pathologist; however, some new pathologic predictors of prognosis and response to therapy are also included.

4 Article Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. 2017

Odgerel, Chimed-Ochir / Takahashi, Ken / Sorahan, Tom / Driscoll, Tim / Fitzmaurice, Christina / Yoko-O, Makoto / Sawanyawisuth, Kittisak / Furuya, Sugio / Tanaka, Fumihiro / Horie, Seichi / Zandwijk, Nico van / Takala, Jukka. ·Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan. · Asbestos Diseases Research Institute, Concord Clinical School, University of Sydney, Sydney, Australia. · Institute of Applied Health Research, University of Birmingham, Birmingham, UK. · School of Public Health, University of Sydney, Sydney, Australia. · Department of Medicine, Division of Hematology, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. · Department of Medicine, Faculty of Medicine, Sleep Apnea Research Group, Khon Kaen University, Khon Kaen, Thailand. · Japan Occupational Safety and Health Resource Center, Tokyo, Japan. · Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. · Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan. · Workplace Safety and Health Institute, Ministry of Manpower, Singapore, Singapore. ·Occup Environ Med · Pubmed #28866609.

ABSTRACT: BACKGROUND: Mesothelioma is increasingly recognised as a global health issue and the assessment of its global burden is warranted. OBJECTIVES: To descriptively analyse national mortality data and to use reported and estimated data to calculate the global burden of mesothelioma deaths. METHODS: For the study period of 1994 to 2014, we grouped 230 countries into 59 countries with quality mesothelioma mortality data suitable to be used for reference rates, 45 countries with poor quality data and 126 countries with no data, based on the availability of data in the WHO Mortality Database. To estimate global deaths, we extrapolated the gender-specific and age-specific mortality rates of the countries with quality data to all other countries. RESULTS: The global numbers and rates of mesothelioma deaths have increased over time. The 59 countries with quality data recorded 15 011 mesothelioma deaths per year over the 3 most recent years with available data (equivalent to 9.9 deaths per million per year). From these reference data, we extrapolated the global mesothelioma deaths to be 38 400 per year, based on extrapolations for asbestos use. CONCLUSIONS: Although the validity of our extrapolation method depends on the adequate identification of quality mesothelioma data and appropriate adjustment for other variables, our estimates can be updated, refined and verified because they are based on commonly accessible data and are derived using a straightforward algorithm. Our estimates are within the range of previously reported values but higher than the most recently reported values.

5 Article Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. 2017

Zonca, Sara / Pinton, Giulia / Wang, Zhuo / Soluri, Maria Felicia / Tavian, Daniela / Griffin, Martin / Sblattero, Daniele / Moro, Laura. ·Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy. · School of Life and Health Sciences, Aston University, Birmingham, UK. · Department of Health Sciences, University of Piemonte Orientale, Novara, Italy. · Laboratory of Cellular Biochemistry and Molecular Biology, CRIBENS, Catholic University of the Sacred Heart, Milan, Italy. · Department of Life Sciences, University of Trieste, Trieste, Italy. ·Cell Death Dis · Pubmed #28151477.

ABSTRACT: Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to environmental/occupational exposure to asbestos, characterized by the presence of significant areas of hypoxia. In this study, we firstly explored the expression and the role of transglutaminase 2 (TG2) in MPM cell adaptation to hypoxia. We demonstrated that cells derived from biphasic MPM express the full-length TG2 variant at higher levels than cells derived from epithelioid MPM and normal mesothelium. We observed a significant induction of TG2 expression and activity when cells from biphasic MPM were grown as a monolayer in chronic hypoxia or packed in spheroids, where the presence of a hypoxic core was demonstrated. We described that the hypoxic induction of TG2 was HIF-2 dependent. Importantly, TGM2-v1 silencing caused a marked and significant reduction of MPM cell viability in hypoxic conditions when compared with normoxia. Notably, a TG2-selective irreversible inhibitor that reacts with the intracellular active form of TG2, but not a non-cell-permeable inhibitor, significantly compromised cell viability in MPM spheroids. Understanding the expression and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic options for MPM treatment.

6 Article Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. 2015

Beckett, P / Edwards, J / Fennell, D / Hubbard, R / Woolhouse, I / Peake, M D. ·Department of Respiratory Medicine, Royal Derby Hospital, Derby, UK; Clinical Standards Department, Royal College of Physicians, London, UK. Electronic address: paul.beckett1@nhs.net. · Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Herries Road, Sheffield, UK. · University of Leicester, Hodgkin Building, Lancaster Road, Leicester, UK. · Nottingham Respiratory Research Unit, Clinical Sciences Building, Nottingham City Hospital, NG5 1PB, UK. · Clinical Standards Department, Royal College of Physicians, London, UK; Department of Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK. · Clinical Standards Department, Royal College of Physicians, London, UK; Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK. ·Lung Cancer · Pubmed #25863904.

ABSTRACT: INTRODUCTION AND METHODS: Malignant pleural mesothelioma (MPM) is an uncommon cancer with poor survival. We have used data collected for the UK National Lung Cancer Audit to assess current practice and to highlight regional variation in the management of mesothelioma patients, as well as to describe survival patterns in subgroups. RESULTS: Our data on 8740 cases seen in hospitals in England and Wales is the largest cohort of MPM in the literature and represents approximately 80% of the total incident cases. 83% are male and median age is 73 years. Performance status is recorded in 81% and of these approximately 70% are PS 0-2. Stage is poorly recorded and unreliable in this dataset. The patient pathway is similar to lung cancer with approximately one-fifth having a non-elective referral to secondary care. A histo-cytological diagnosis is made in 87% and varies across organisations. Only 67% have anti-cancer treatment, and this also varies across organisations, but there has been an annual increase in the proportion receiving chemotherapy. Overall median survival was 9.5 months, with a 1YS of 41.4% and 3YS of 12.0%, but was strongly linked to performance status and histological subtype. Median survival also varied by cancer network from 209 days to 349 days, but appeared to increase from of 9.2 months in 2008 to 10.5 months in 2012. CONCLUSION: Our data provide a large scale, detailed assessment of MPM epidemiology, treatment choices and outcomes. Incidence is increasing in line with predictions and uptake of treatments has generally mirrored publication of key MPM treatment trials, in particular increasing use of chemotherapy but low uptake of radical surgery. However, there is significant variation in care patterns and outcomes that may reflect limited expertise in area with low incidence. Initiatives to improve outcomes should include improved recording of clinical stage.

7 Article Cancer incidence in UK electricity generation and transmission workers, 1973-2008. 2012

Sorahan, T. ·Institute of Occupational and Environmental Medicine, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. T.M.Sorahan@bham.ac.uk ·Occup Med (Lond) · Pubmed #22949586.

ABSTRACT: BACKGROUND: The effects of magnetic field exposure on cancer risks remains unclear. AIMS: To examine cancer incidence among a cohort of UK electricity generation and transmission workers. METHODS: Cancer morbidity experienced by a cohort of 81 842 employees of the former Central Electricity Generating Board of England and Wales was investigated for the period 1973-2008. All employees had worked for at least 6 months with some employment between 1973 and 1982. Standardized registration ratios (SRRs) were calculated on the basis of national rates. RESULTS: Overall cancer morbidity was slightly below expectation in males and females. Significant excesses were found in male workers for mesothelioma (Observed [Obs] 504, SRR 331), skin cancer (non-melanoma) (Obs 3187, SRR 107) and prostate cancer (Obs 2684, SRR 107) and in female workers for cancer of the small intestine (Obs 10, SRR 306) and nasal cancer (Obs 9, SRR 474). Brain cancers were close to expectation in males and below expectation in females. Leukaemia incidence (all types) was slightly below expectation in males and females. More detailed analyses showed import ant contrasts for mesothelioma and leukaemia. CONCLUSIONS: The clear occupational excess of mesothelioma was not matched by a corresponding excess of lung cancer, and the level of asbestos-induced lung cancer in this industry must be low. Leukaemia risks declined with period from hire; confident interpretation of this finding is not possible. The excesses of cancers of the nasal cavities and small intestine are probably not occupational, though the excess of skin cancer may be due to outdoor work.

8 Article Three decades of experience in the surgical multi-modality management of pleural mesothelioma. 2010

Luckraz, Heyman / Rahman, Mesbah / Patel, Nishith / Szafranek, Adam / Gibbs, Allen R / Butchart, Eric G. ·Heart and Lung Centre, New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom. HeymanLuckraz@aol.com ·Eur J Cardiothorac Surg · Pubmed #19717307.

ABSTRACT: BACKGROUND: Optimal management of diffuse malignant pleural mesothelioma (DMPM) remains unclear. We report our 30-year surgical experience with DMPM with emphasis on surgical procedure and post-operative adjuvant therapy. METHODS: During the period of the study, 217 patients with DMPM were referred for surgical opinion. Patients who only had pleural biopsies were excluded (n=78). Consecutive patients who underwent surgical treatment were included (n=139). Surgical options were extra-pleural pneumonectomy (EPP) for Butchart stage I disease in clinically fit patients (n=49) or pleurectomy/decortication in patients who were either not fit for EPP or had advanced disease (Butchart stage II and III) or both (n=90). Post-operative adjuvant therapy included either chemotherapy, radiotherapy, both or none. RESULTS: The median follow-up was 10.0 months. The longest survival (median 26.0 months, IQR: 11.14-40.9 months) occurred in the pleurectomy/decortication group who received both post-operative chemotherapy and radiotherapy (n=24) (p<0.001). EPP whether or not combined with adjuvant therapy provided no significant survival advantage in comparison to pleurectomy/decortication (overall median survival 10.3 months vs 10.1 months, p=0.09). On univariate analysis, pleurectomy/decortication combined with chemotherapy and radiotherapy was the strongest predictor of prolonged survival (Hazard Ratio=3.6). Multivariate analysis with the inclusion of histological type, surgical procedure and type of adjuvant therapy, EPP without adjuvant therapy was an independent risk-factor for decreased survival (Hazard Ratio=9.2). CONCLUSIONS: In this series, cytoreductive surgery combined with post-operative adjuvant therapy provided better survival despite either advanced disease or surgically less fit patients. Thus, pleurectomy/decortication may be the procedure of choice, given that neither surgical procedure (EPP or PD) is not curative.

9 Minor The Effect of Benign and Malignant Pleural Disease on Chest Wall Mechanics. 2017

Elshafie, Ghazi / Kumar, Prem / Djearaman, Madava / Aliverti, Andrea / Naidu, Babu. ·1 Heart of England National Health Service Foundation Trust Birmingham, United Kingdom. · 2 Queen Elizabeth Hospital Birmingham Birmingham, United Kingdom and. · 3 Politecnico di Milano Milano, Italy. ·Am J Respir Crit Care Med · Pubmed #28707974.

ABSTRACT: -- No abstract --